CARMAT

About CARMAT

Carmat (CARMAT SA) is a French medical technology company specializing in the development of the Aeson® total artificial heart, an implantable bioprosthetic device designed to provide a long-term solution for patients suffering from end-stage biventricular heart failure. Founded with the goal of bridging the gap between organ shortage and patient need, Carmat combines advanced engineering, biomaterials, and medical innovation to replicate the natural function of the human heart.

The Aeson system mimics both the structure and performance of a biological heart. It uses sensors, microprocessors, and biocompatible materials to automatically adjust blood flow according to the patient’s physical activity, ensuring physiological balance and improved quality of life. The external power and control unit allows recipients to move freely while maintaining continuous cardiac support.

Developed through collaboration with cardiac surgeons, engineers, and scientific partners, Aeson represents a major advance in the field of cardiac prosthetics. It is designed not only as a bridge to transplant but also as a potential permanent replacement therapy for patients who are not eligible for donor hearts.

Carmat continues to work toward expanding the availability of Aeson through clinical studies and regulatory partnerships, with a focus on improving long-term patient outcomes and advancing the frontier of artificial organ technology.